Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.

The NEJM has published the results of a French multicenter study showing that prosthetic joint infections can be successfully managed with 6 weeks of antibiotic therapy; this was noninferior and had better outcomes compared to 12 weeks of antibiotic therapy.

House lawmakers on both sides of the aisle pummeled AbbVie CEO Richard Gonzalez for raising the price of two widely used drugs and for the company's "legally questionable" tactics to head off competition from biosimilars, despite pulling in healthy profits.

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Patients with psoriasis or psoriatic arthritis who were being treated with ustekinumab (Stelara) had lower rates of serious hospitalized infections than patients receiving other biologics or small molecule therapies, a study utilizing data from two commercial claims databases found.

Tildrakizumab, a monoclonal antibody targeting interleukin-23p19 studied in adults with psoriatic arthritis (PsA), was found to be superior to placebo and well tolerated without reports of uveitis, systemic fungal infections, inflammatory bowel disease, major cardiac events or death. 

RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).

NSAIDs do not affect COVID outcomes; here we are nearly 16 months into the pandemic, and this is the common sense conclusion of a recent trial published in Lancet Rheumatology.

Last month, psoriasis patients covered by Cigna received a curious letter from the insurance giant's pharmacy management division.

Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.

The predictive value of therapeutic drug monitoring (TDM) while on biologics is debateable; gastroenterology routinely relies on TDM, while rheumatologists do not.